ImmunisLogoWImmunisLogocropped-immunislogo.pngcropped-immunislogo.png
  • Home
  • About
  • Technology
  • Clinical Trials
  • News
  • Media
  • Contact
✕
  • Home
  • CBS2 News Highlights Mission Plasticos, A Non-profit Providing Free Reconstructive Surgery to Underserved Populations [video]
Immunis Chairman Dr. Hans Keirstead Meets With His Holiness the Dalai Lama [photos]
Immunis Chairman Dr. Hans Keirstead Recognized as a Top Orange County Business Leader
November 1, 2022
IRVINE, Calif. — November 1, 2022 — Immunis Chairman, Dr. Hans Keirstead, is the Board Chair of Mission Plasticos. Mission Plasticos is a non profit providing FREE reconstructive surgery to underserved populations in medical need. Please check out the segment from CBS2 News highlighting the importance of this life-changing work!

About Mission Plasticos

Mission Plasticos is a non-profit program founded in 1999 by Dr. Larry Nichter, Orange County plastic surgeon. He was later joined by Dr. Jed Horowitz whose artistry has been key to the success for his thousands of cosmetic procedures. Their mission is to provide worldwide reconstructive plastic surgical care to enhance the lives of those with correctable deformities. Mission Plasticos primarily performs surgeries in underdeveloped and poverty-stricken countries outside of the United States where children are frequently born with congenital disfigurements. Another goal of Mission Plasticos is to advance the field of Plastic Surgery through training, research, and public education of surgeons, enabling them to carry on this work in their home countries. For additional information, please visit: www.plasticosfoundation.org

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

###

Share

Recent News

  • Sep 28, 2023

    Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board

  • Sep 26, 2023

    Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics in Basel

  • Aug 30, 2023

    Immunis Wins Corporate LiveWire’s 2023 “Innovation and Excellence Award”

Navigation

  • Home
  • About
  • Technology
  • Clinical Trials
  • News
  • Media
  • Contact

Contact info

Immunis, Inc.
Irvine, California


contact@immunisbiomedical.com

© 2023 Immunis, Inc. | All Rights Reserved